Covariate adjustment in clinical trials with non-ignorable missing data and non-compliance

Statistics in Medicine

Volumn 23, Issue 15, 2004, Pages 2319-2339

  Levy, Douglas E ^a   O'Malley, A James ^a   Normand, Sharon Lise T ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Covariate adjustment; Instrumental variables; Missing data; Non compliance; Randomized clinical trials

Indexed keywords

CLOZAPINE; HALOPERIDOL;

AGRANULOCYTOSIS; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COVARIANCE; DRUG EFFICACY; DRUG FATALITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; MUSCLE STIFFNESS; PATIENT COMPLIANCE; SCHIZOPHRENIA; SIMULATION; STATISTICAL CONCEPTS; TREATMENT OUTCOME; TREMOR;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; EMPIRICAL RESEARCH; HALOPERIDOL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA;

EID: 4344585582     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1848     Document Type: Article

References (18)

1. Rubin DB. Estimating causal effects of treatments in randomized and non-randomized studies. Journal of Educational Psychology 1974; 66(5):688-701.
2. Song F. Risperidone in the treatment of schizophrenia: a meta-analysis of RCTs. Journal of Psychopharmacology 1997; 11(1):65-71.
3. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone vs other atypical antipsychotic medications for schizophrenia (review). Cochrane Database of Systematic Reviews 2000; 3:CD002306.
4. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology 2001; 155(3):230-233.
5. Angrist J, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. Journal of the American Statistical Association 1996; 91(434):444-472.
6. Zelen M. A new design for randomized, clinical trials. New England Journal of Medicine 1979; 300(22): 1242-1245.
7. Zelen M. Randomized consent designs for clinical trials: an update. Statistics in Medicine 1990; 9(6):645-656.
8. Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70(1):41-55.
9. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11(5):550-560.
10. Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. Journal of the American Statistical Association 1991; 86(413):9-26.
11. Frangakis CE, Rubin DB. Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment non-compliance and subsequent missing outcomes. Biometrika 1999; 86(2):365-379.
12. Cox DR, McCullagh P. Some aspects of analysis of covariance. Biometrics 1982; 38(3):541-561.
13. Raab GM, Day S, Sales J. How to select covariates to include in the analysis of a clinical trial. Controlled Clinical Trials 2000; 21(4):330-342.
14. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A Comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 1997; 337(12):809-815.
15. Tanner MA. Tools for Statistical Inference: Methods for the Exploration of Posterior Distributions and Likelihood Functions, Chapter 2. Springer: New York, 1993; 26-27.
16. Efron B. Bootstrap confidence intervals for a class of parametric problems. Biometrika 1985; 72(1):45-58.
17. Efron B. Better bootstrap confidence intervals (C/R: p186-200). Journal of the American Statistical Association 1987; 82(397):171-185.
18. Shao J. On resampling methods for variance and bias estimation in linear models. Annals of Statistics 1988; 16(3):986-1008.